Related Experiment Video
Updated: May 4, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions
Saeedeh Ravi1, Mohsen Nasiri-Toosi, Iman Karimzadeh
1Tehran University of Medical Sciences, Department of Clinical Pharmacy, Faculty of Pharmacy , Postal Code: 1417614411, P.O. Box: 14155/6451, Tehran , IR Iran +98 9122979329 ; +98 2166461178 ; khalilih@tums.ac.ir.
Objectives:
To assess the pattern and possible risk factors of conventional and/or pegylated interferon alpha (IFN-α) plus ribavirin therapy for causing adverse reactions in patients with chronic hepatitis C virus. Patients attending a referral center in Iran were assessed.
Methods:
During an 18 month period all adult individuals diagnosed with chronic hepatitis C virus who planned to receive anti-hepatitis C virus treatment were prospectively screened regarding all related subjective and objective adverse drug reactions.
Results:
The number of adverse drug reactions were significantly associated with the number of concomitant medications (p < 0.001), female gender (p = 0.027), increased age (p = 0.001), pegylated IFN-α (p = 0.015) and hepatitis C virus genotype 1 (p = 0.002). History of a prior anti-hepatitis C virus treatment course (OR = 3.081, 95% CI = 1.174 - 6.085; p = 0.022) and the number of co-administered medications (OR = 1.165, 95% CI = 1.034 - 1.314; p = 0.012) were identified as the only statistically significant risk factors for developing anti-hepatitis C virus medication-related psychiatric and dermatologic adverse reactions, respectively.
Conclusion:
These data could be exploited by health-care professionals and policy makers as a guide for developing optimal educational and preventive strategies in the setting of anti-hepatitis C virus medication safety.
Related Concept Videos
Hepatitis
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Risk factors
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hypersensitivity Reactions: Cytolytic Reactions

